Milan (askanews) – Intense itching to prevent sleep. It is the main symptom of atopic dermatitis, the most common inflammatory disease of the skin, affecting 5 to 8 percent of the adult population, and is characterized by the most common skin lesions in the most severe forms. body.
A disease in the most acute, inhibitory forms. However, the first biological therapy reimbursed by the National Health Service for patients today can be used for the treatment of severe atopic dermatitis in which adult ciclosporin treatment is contraindicated, ineffective or tolerable.
Giampiero Girolomoni, professor of dermatology at the University of Verona, says: ilebilir Atopic dermatitis can be treated today: there is a new drug called Dupilumab approved by AIFA, which allows to treat moderate and severe forms. is a very effective disease, combined with an excellent safety profile.It is a drug – the professor continue – is extremely well tolerated, does not have drug interactions, does not require monitoring of laboratory tests, is administered subcutaneously every two weeks and Da and at least two years of experience in Northern Europe in the vast majority of patients 39.
Dupilumab was included in the list of innovative medicines of the Italian Drug Agency. But what are the therapeutic advantages associated with its use? V The added value of Dupilumab is its ability to control the symptoms and symptoms of atopic dermatitis in the long term, ad said Antonio Costanzo, head of the Dermatology Operating Unit at the Humanitas Clinical Institute in Rozzano. Atopic dermatitis is a disease characterized by lesions. It is quite itchy skin. Dupilumab is an intense pruritus that makes sleep difficult, Dupilumab can control skin lesions and control prolonged itching without side effects. "
For the Italian Association of Atopic Dermatitis, which represents patients, the introduction of the new drug represents "a true revolution in treatment, 50 years after a real revolution for those affected by the disease".